Alec Goldenberg is an Oncology physician affiliated with Manhattan Physical Medicine and Rehabilitation. OpenAlex indexes 58 publications with 1,733 citations (h-index 20); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
157 East 32nd Street
2nd Floor
New York, NY 100166028
Telephone
212-689-6791Registry record last updated 2 Dec 2009.
Clinical trials
- Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
45 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20255 payments
- Aveo Pharmaceuticals, Inc.Program year20254 payments
- Celgene CorporationProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
73%Parenteral Iron Replacement64.6%Iron sucrose100%Part B, office-administered≥49 patientsErythropoiesis-stimulating Agent8.1%Epoetin alfa98%Procrit2%Retacrit1%Part D + Part B<11 patients+ 4 more classes in this area
Sensory organs
22.1%Corticosteroid22.1%Dexamethasone sodium phosphate100%Dexamethasone0%Part D + Part B<11 patientsCancer & immunology
1.3%Kinase inhibitor0.2%Jakafi35%Imbruvica25%Calquence24%Brukinsa16%Part D<11 patientsCD20-directed Cytolytic Antibody0.2%Gazyva52%Truxima29%Ruxience19%Part D<11 patients+ 18 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2007–2007 per NIH RePORTER. The latest:
- BEVACIZUMAB IN HEPATOCELLULAR CANCER FOR PATIENTS WITH UNRESECTABLE TUMOR
New York University School of Medicine
FY2007$7,891M01RR000096
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).
Journal of Clinical Oncology
2022 - Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).
Journal of Clinical Oncology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”